APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rx Irritable Bowel Syndrome (IBS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Analysis and Forecast 2026-2032

Report ID 174033660219 December 2025199 pages

Choose your research edition.

Industry ResearchRx Irritable Bowel Syndrome (IBS) Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Rx Irritable Bowel Syndrome (IBS) Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Rx Irritable Bowel Syndrome (IBS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rx Irritable Bowel Syndrome (IBS) Drugs include Allergan, Bausch Health, Ironwood Pharmaceuticals, Sebela Pharmaceuticals and Takeda, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rx Irritable Bowel Syndrome (IBS) Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rx Irritable Bowel Syndrome (IBS) Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Rx Irritable Bowel Syndrome (IBS) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rx Irritable Bowel Syndrome (IBS) Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rx Irritable Bowel Syndrome (IBS) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rx Irritable Bowel Syndrome (IBS) Drugs revenue, projected growth trends, production technology, application and end-user industry.

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Company

Allergan

Bausch Health

Ironwood Pharmaceuticals

Sebela Pharmaceuticals

Takeda

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Type

IBS-D Drugs

IBS-C Drugs

Others

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Application

Women

Men

Rx Irritable Bowel Syndrome (IBS) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rx Irritable Bowel Syndrome (IBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rx Irritable Bowel Syndrome (IBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rx Irritable Bowel Syndrome (IBS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rx Irritable Bowel Syndrome (IBS) Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rx Irritable Bowel Syndrome (IBS) Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rx Irritable Bowel Syndrome (IBS) Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. IBS-D Drugs Major Player Table 3. IBS-C Drugs Major Player Table 4. Others Major Player Table 5. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Women Major Player Table 7. Men Major Player Table 8. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends Table 9. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Drivers Table 10. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Opportunities and Challenges Table 11. Rx Irritable Bowel Syndrome (IBS) Drugs Industry Restraints Table 12. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region (2021-2026) Table 15. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region (2027-2032) Table 17. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Headquarters & Area Served Table 21. Global Rx Irritable Bowel Syndrome (IBS) Drugs Players, Product Type & Application Table 22. Global Rx Irritable Bowel Syndrome (IBS) Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Rx Irritable Bowel Syndrome (IBS) Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2027-2032) Table 35. Allergan Company Information Table 36. Allergan Business Overview Table 37. Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 39. Allergan Recent Development Table 40. Bausch Health Company Information Table 41. Bausch Health Business Overview Table 42. Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 44. Bausch Health Recent Development Table 45. Ironwood Pharmaceuticals Company Information Table 46. Ironwood Pharmaceuticals Business Overview Table 47. Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 49. Ironwood Pharmaceuticals Recent Development Table 50. Sebela Pharmaceuticals Company Information Table 51. Sebela Pharmaceuticals Business Overview Table 52. Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 54. Sebela Pharmaceuticals Recent Development Table 55. Takeda Company Information Table 56. Takeda Business Overview Table 57. Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio Table 59. Takeda Recent Development Table 60. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 61. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 62. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 63. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 64. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 65. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 67. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 68. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 69. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 70. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 71. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 73. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 74. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 75. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 76. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 77. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 78. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 79. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 80. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 81. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 82. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 83. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Region (US$ Million) & (2021-2026) Table 84. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Region (US$ Million) & (2027-2032) Table 85. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 86. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 87. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 88. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 89. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 91. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (US$ Million) & (2027-2032) Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Rx Irritable Bowel Syndrome (IBS) Drugs Image Figure 2. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. IBS-D Drugs Image Figure 5. IBS-C Drugs Image Figure 6. Others Image Figure 7. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Women Image Figure 10. Men Image Figure 11. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Rx Irritable Bowel Syndrome (IBS) Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032) Figure 24. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032) Figure 25. North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Country (2021-2032) Figure 26. United States Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032) Figure 43. China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Rx Irritable Bowel Syndrome (IBS) Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D Drugs
  • IBS-C Drugs
  • Others
Applications
  • Women
  • Men
Companies covered
  • Allergan
  • Bausch Health
  • Ironwood Pharmaceuticals
  • Sebela Pharmaceuticals
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rx Irritable Bowel Syndrome (IBS) Drugs Market by Type
  3. 1.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 IBS-D Drugs
  5. 1.2.3 IBS-C Drugs
  6. 1.2.4 Others
  7. 1.3 Rx Irritable Bowel Syndrome (IBS) Drugs Market by Application
  8. 1.3.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Women
  10. 1.3.3 Men
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Rx Irritable Bowel Syndrome (IBS) Drugs Market Dynamics
  1. 2.1 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends
  2. 2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Drivers
  3. 2.3 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Opportunities and Challenges
  4. 2.4 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Perspective (2021-2032)
  2. 3.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Growth Trends by Region
  3. 3.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Players
  2. 4.1.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Rx Irritable Bowel Syndrome (IBS) Drugs Players, Product Type & Application
  8. 4.5 Global Rx Irritable Bowel Syndrome (IBS) Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market CR5 and HHI
  11. 4.6.3 2025 Rx Irritable Bowel Syndrome (IBS) Drugs Tier 1, Tier 2, and Tier 3
5 Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Type
  1. 5.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2021-2032)
6 Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Application
  1. 6.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Bausch Health
  8. 7.2.1 Bausch Health Company Information
  9. 7.2.2 Bausch Health Business Overview
  10. 7.2.3 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  12. 7.2.5 Bausch Health Recent Developments
  13. 7.3 Ironwood Pharmaceuticals
  14. 7.3.1 Ironwood Pharmaceuticals Company Information
  15. 7.3.2 Ironwood Pharmaceuticals Business Overview
  16. 7.3.3 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  18. 7.3.5 Ironwood Pharmaceuticals Recent Developments
  19. 7.4 Sebela Pharmaceuticals
  20. 7.4.1 Sebela Pharmaceuticals Company Information
  21. 7.4.2 Sebela Pharmaceuticals Business Overview
  22. 7.4.3 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  24. 7.4.5 Sebela Pharmaceuticals Recent Developments
  25. 7.5 Takeda
  26. 7.5.1 Takeda Company Information
  27. 7.5.2 Takeda Business Overview
  28. 7.5.3 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Product Portfolio
  30. 7.5.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (2021-2032)
  2. 8.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country
  11. 8.6.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (2021-2032)
  2. 9.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country
  11. 9.6.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (2021-2032)
  2. 10.2 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032)
  5. 10.3 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032)
  9. 10.5 China Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (2021-2032)
  2. 11.2 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country
  11. 11.6.1 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country
  11. 12.6.1 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst